Associated diseases and diuretic dosage to predict mortality in transthyretin amyloid cardiomyopathy

Archives of cardiovascular diseases 2026 Open access

Read full text
Authors: Vincent Algalarrondo, Olivier Lairez, Marion Narbeburu, Pauline Fournier, JEROME F. COSTA, Françoise Pelcot, Agnes FARRUGIA, Isabelle Durand-Zaleski, Herve Lilliu, Mathilde Bartoli, Stéphane Fievez, Jérémie Rudant
+8 more Agathe Coste, Charlotte Noirot Cosson, Pierre-Alexandre Squara, Giorgia Canali, B. de Neuville, Michel Slama, Philippe Charron, Thibaud Damy
DOI: 10.1016/j.acvd.2025.10.333
Cited by: 0
References: 20

Abstract

BACKGROUND: Transthyretin amyloidosis can lead to transthyretin amyloid cardiomyopathy (ATTR-CM) and heart failure. AIMS: To describe the prevalence of cardiac and extracardiac diseases in patients with ATTR-CM and examine mortality predictors, including diuretic dosage, using the French National Health Database. METHODS: Patients with ATTR-CM and their medical characteristics were identified from the French database from 2011 to 2019. Diuretic doses were categorized into four classes (furosemide dose: level 1

Fields of Study & Subjects

Amyloidosis: Diagnosis Treatment Outcomes Parathyroid Disorders and Treatments Intracerebral and Subarachnoid Hemorrhage Research

Publication details

Journal / source
Archives of cardiovascular diseases
Volume
119
Issue
5
Pages
341–347
Publication date
7 January 2026
Language
EN